Manufacturing growth sees surging demand at CPhI South East Asia

3 May 2019

Number of visitors seeking a contract manufacturer was extremely high, with multinational corporations increasingly looking for local partners to expedite market access into the wider region.

SE Asian demand for manufacturing is being driven by recent regulatory changes and increased generics from Indonesia, Malaysia and the Philippines. These prosperous regional conditions were in evidence at the largest ever CPhI South East Asia (8th edition), which closed late last month. The event’s move from Indonesia to Thailand was extremely successful, with the new Bangkok location booming in just its first year of operation.

Manufacturing growth sees surging demand at CPhI South East Asia

One of the emerging trends reported by exhibitors was the increased internationalisation, and this was a common theme running throughout the show, whether it was content from sessions about the FDA Framework and requirements for importing APIs to an increased number of regional distributors. In addition, the number of visitors seeking a contract manufacturer was extremely high, further indicative of the internationalisation of the ASEAN pharma industry, with multinational corporations increasingly looking for local partners to expedite market access into the wider region.

The ASEAN’s market is widely expected to see robust growth through 2019 into 2020 in part thanks to its diversity of opportunity. The region features a good mix of rapidly gentrifying healthcare economies in Thailand and Vietnam, coupled advanced economies with significant high-value manufacturing in Singapore, as well as large patient population countries with an ever increasing demand for generics in Malaysia, Indonesia and Philippines.

Often seen as an indicator of ASEAN pharma’s overall health, the success of CPhI South East Asia suggests a thriving pharma sector in the region. Indicative of this region’s overall prosperity, the show has seen an increase of more than 50% in attendees, with almost 7,250 unique attendees and more than 250 exhibitors over 3 days. Such was the strength of the show’s new country, CPhI South East Asia will be moving to the IMPACT, Muang Thong Thani in Bangkok next year where event organisers anticipate an even larger offer onsite and more international visitors.

“It was such a successful edition. The ASEAN pharma market is one that is now brimming with potential and is already reaping the rewards of recent regulatory reforms. CPhI South East Asia has established itself as the region’s business hub, attracting everyone from ingredient suppliers to distributors and CMOs, coming from an increasing diverse range of countries. What is most rewarding is that this show has been integral to industry growth over the last year, with the constant exchanging of ideas and widening business networks playing a pivotal role,” said Marie Lagrenee, Brand Manager at CPhI South East Asia.

In 2020, CPhI South East Asia will co-locate with FDF, ICSE, P-MEC, InnoPack, and NEX South East Asia with Informa expecting to welcome more than 6,000 attendees and 275 exhibitors. Executives attend from across the region’s fastest growing pharma segments, with packaging experts, machinery providers and contract manufacturing, as well as an emerging nutraceutical and laboratory sector – facilitating a collective environment that is helping sustain the next stage in the ASEAN pharma expansion.

Read More

Related news

Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
China on course for 'massive' bio capacity shortfall

China on course for 'massive' bio capacity shortfall

4 Nov 2019

A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

Read more 
German pharma benefiting from a Brexit boost?

German pharma benefiting from a Brexit boost?

24 Oct 2019

Germany establishes itself as Europe's leading pharma market in 2019.

Read more 
The talk of the show?

The talk of the show?

23 Oct 2019

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPhI WW.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more 
Cytel to hold Complex Innovative Trial Design Symposium

Cytel to hold Complex Innovative Trial Design Symposium

18 Oct 2019

Experts to discuss innovative solutions to rare disease clinical trials.

Read more 
Finalists announced for this year's CPhI Worldwide Awards

Finalists announced for this year's CPhI Worldwide Awards

17 Oct 2019

The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more